Abstract
Beyond pharmacological approaches to the treatment of memory loss that results from Alzheimer's disease or stroke, there lies a broad diagnostic penumbra of 'age-associated memory impairment'. New research that offers to attain the ancient goal of improving our cognitive ability raises an important issue — the use, by healthy people, of such pharmacological tools as cognitive enhancers. Here, I review the history and effectiveness of such supposed 'nootropics', and the ethical, social and legal issues raised by their potential use in disease and in the enhancement of 'normal' cognition.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics
Substance Abuse Treatment, Prevention, and Policy Open Access 01 February 2014
-
The Future of Psychopharmacological Enhancements: Expectations and Policies
Neuroethics Open Access 11 February 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Langreth, R. Viagra for the brain. Forbes Magazine (4 February 2002).
Tang, Y. P. et al. Enhancement of learning and memory in mice. Nature 401, 63–69 (1999).
Giurgea, C. Vers une pharmacologie de l'activité integrative du cerveau. Tentative du concept nootrope en psychopharmacologie. Actual. Pharmacol. (Paris) (1972).
Sara, S. J. On the use and usefulness of cognitive enhancing drugs. ESF and Wenner–Gren Foundation Symposium, Perils and Prospects of the new Brain Sciences Abstacts (Stockholm, 2001).
Dean, W. & Morgenthaler, J. Smart Drugs and Nutrients (B & J Publications, Santa Cruz, California, 1991).
Balota, D. A., Dolan, P. O. & Duchek, J. M. in The Oxford Handbook of Memory (eds Tulving, E. & Craik, F. I. M.) 395–409 (Oxford Univ. Press, Oxford, UK, 2000).
Bolla, K. I., Lindgren, K. N., Bonaccorsy, C. & Bleecker, M. L. Memory Complaints in older adults: fact or fiction? Arch. Neurol. 48, 61–65 (1991).
Rose, S. P. R. The Making of Memory 2nd edn (Cape, London, in the press).
Yates, F. The Art of Memory (Penguin, London, 1966).
Loftus, E. & Ketchum, K. The Myth of Repressed Memory: False Memories and Allegations of Sexual Abuse (St Martin's Press, New York, 1994).
Schachter, D. L. Searching for Memory: the Brain, the Mind and the Past (HarperCollins, New York, 1997).
Luria, A. R. The Mind of a Mnemonist (Cape, London, 1969).
Borges, J. L. Funes the Memorious (Calder, London, 1965).
Sandi, C. & Rose, S. P. R. Training-dependent biphasic effects of corticosterone in memory formation for a passive avoidance task in chicks. Psychopharmacology (Berl.) 133, 152–160 (1997).
McGaugh, J. L. & Roozendaal, B. Role of adrenal stress hormones in forming lasting memories in the brain. Curr. Opin. Neurobiol. 12, 205–210 (2002).
Gold, P. E. Glucose modulation of memory storage processing. Behav. Neural Biol. 45, 145–155 (1986).
Gouliaev, A. H. & Senning, A. Piracetam and other structurally related nootropics. Brain Res. Rev. 19, 180–222 (1994).
Mondadori, C. The pharmacology of the nootropics: new insights and new questions. Behav. Brain Res. 59, 1–9 (1993).
Kramer, P. D. Listening to Prozac (Viking, New York, 1997).
Burbach, J. P. H. & de Wied, D. Brain Functions of Neuropeptides (Parthenon, Carnforth, UK, 1993).
Migues, P. V., Johnston, A. N. B. & Rose, S. P. R. Dehydroepiandosterone and its sulphate enhance memory retention in day-old chicks. Neuroscience 109, 243–251 (2002).
Johnston, A. N. B. & Rose, S. P. R. Memory consolidation in day-old chicks requires BDNF but not NGF or NT-3: an antisense study. Mol. Brain Res. 88, 26–36 (2001).
Paganini-Hill, A. & Henderson, V. W. Estrogen deficiency and risk of Alzheimer's Disease in women. Am. J. Epidemiol. 140, 256–261 (1994).
British Medical Association & Royal Pharmaceutical Society of Great Britain. British National Formulary (Pharmaceutical Press, Oxford, UK, 2001).
Hartmann, H., Eckert, A. & Muller, W. E. Disturbances of the neuronal calcium homeostasis in the aging nervous system. Life Sci. 55, 2011–2018 (1994).
Quartermain, D., deSoria, V. G. & Kwan, A. Calcium channel antagonists enhance retention of passive avoidance and maze learning in mice. Neurobiol. Learn. Mem. 75, 77–90 (2001).
Robbins, T. W., McAlonan, G., Muir, J. L. & Everitt, B. J. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive defects in Alzheimer's disease. Behav. Brain Res. 83, 15–23 (1997).
Furey, M. L., Pietrini, P. & Haxby, J. V. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 290, 2315–2318 (2000).
Rose, S. P. R. God's organism. The chick as a model for the study of learning and memory. Learn. Mem. 7, 1–17 (2000).
Izquierdo, I. & Medina, J. H. Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures Neurobiol. Learn. Mem. 68, 285–316 (1997).
Poschel, B. P. H. in Handbook of Psychopharmacology (ed. Iversen, L. L.) 11–25 (Plenum, New York, 1988).
Cenni, A., Puliti, R., De Regis, M., Viggiani, P. & Spignoli, G. Pharmacological properties of a nootropic agent of endogenous origin. J. Drug Dev. 1, 157–162 (1988).
Muller, W. E., Scheur, K. & Stoll, S. Glutamatergic treatment strategies for age-related memory disorders. Life Sci. 55, 2147–2153 (1994).
Yin, J. C. P., Del Vecchio, M., Zhou, H. & Tully, T. CREB as a memory modulator: induced expression of a dCREB2 activator isoform enhances long-term memory in Drosophila. Cell 81, 107–115 (1995).
Bourtchouladze, R. et al. Deficient long-term memory in mice with a targeted mutation in the cAMP-responsive element binding protein. Cell 79, 59–68 (1994).
Kogan, J. H. et al. Spaced training induces normal long-term memory in CREB mutant mice. Curr. Biol. 7, 1–11 (1997).
Schenk, D. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nature Rev. Neurosci. 3, 824–828 (2002).
Sacks, O. Awakenings (Random House, New York, 1976).
Nuffield Council on Bioethics. Genetics and Human Behaviour: the Ethical Context (Nuffield Council, London, 2002).
Cornwell, J. The Power to Harm: Mind, Medicine and Murder on Trial (Penguin, Harmondsworth, UK, 1998).
McGaugh, J. L. Enhancing cognitive performance. South. Calif. Law Rev. 65, 383–395 (1991).
Rees, D. & Rose, S. P. R. (eds) Prospects and Perils of the New Brain Sciences (Cambridge Univ. Press, New York, in the press).
Acknowledgements
I thank J. McGaugh, E. Giacobini and P. Giese for comments on earlier drafts of this review.
Author information
Authors and Affiliations
Related links
Related links
DATABASES
LocusLink
brain-derived neurotrophic factor
OMIM
FURTHER INFORMATION
Encyclopedia of Life Sciences
Rights and permissions
About this article
Cite this article
Rose, S. 'Smart Drugs': do they work? Are they ethical? Will they be legal?. Nat Rev Neurosci 3, 975–979 (2002). https://doi.org/10.1038/nrn984
Issue Date:
DOI: https://doi.org/10.1038/nrn984
This article is cited by
-
Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics
Substance Abuse Treatment, Prevention, and Policy (2014)
-
The warrior in the machine: neuroscience goes to war
Nature Reviews Neuroscience (2014)
-
The molecular and cellular biology of enhanced cognition
Nature Reviews Neuroscience (2009)
-
Genotype-dependent characteristics of behavior in mice in cognitive tests. The effects of Noopept
Neuroscience and Behavioral Physiology (2009)
-
The Future of Psychopharmacological Enhancements: Expectations and Policies
Neuroethics (2009)